title: [The return of germline gene therapy].
abstract: The recent development of a powerful and flexible genome editing technique (the CRISP-cas9 method) accelerates tremendously the production of animal models and will significantly enhance the perspectives of (somatic) gene therapy. However, it also raises a real possibility of germline modifications in humans, with therapeutic aims or for "improvement": this raises thorny ethical questions that are no longer theoretical (as in the 1990s) but will have to be faced in the very near future.
authors.affiliation: UMR 7268 ADÉS, Aix-Marseille, Université/EFS/CNRS, Espace éthique méditerranéen, hospital d'adultes la Timone, 264, rue Saint-Pierre, 13385 Marseille Cedex 05, France - CoReBio PACA, case 901, parc scientifique de Luminy, 13288 Marseille Cedex 09, France.
authors.forename: Bertrand
authors.initials: B
authors.lastname: Jordan
mesh_terms: D032984:Ethics, Research; D015316:Genetic Therapy / Q000941:ethics / Q000379:methods / Q000639:trends*; D005854:Germ Cells / Q000166:cytology / Q000502:physiology; D018095:Germ-Line Mutation / Q000235:genetics*; D006801:Humans; D057905:Stem Cell Research / Q000941:ethics